Early treatment in HCV: is it a cost-utility option from the Italian perspective?

Andrea Marcellusi; Raffaella Viti; Francesco Damele; Calogero Camma; Gloria Taliani; Francesco Saverio Mennini

doi:10.1007/s40261-016-0414-y

Early treatment in HCV: is it a cost-utility option from the Italian perspective?

Andrea Marcellusi
, Raffaella Viti
, Francesco Damele
, Calogero Camma
, Gloria Taliani
, Francesco Saverio Mennini

Research output: Contribution to journal › Article › peer-review

Abstract

Our model represents a tool for policy makers and health-care professionals, and provided information on the cost-utility of the early-treatment approach in HCV-infected patients in Italy. Starting innovative treatment regimens earlier keeps HCV-infected patients in better health and reduces the incidence of HCV-related events; generating a gain both in terms of health of the patients and correct resource allocation.

Original language	English
Pages (from-to)	661-672
Journal	Clinical Drug Investigation
Volume	36
Issue number	8
Early online date	27 May 2016
DOIs	https://doi.org/10.1007/s40261-016-0414-y
Publication status	Published - Aug 2016

Keywords

Business and management studies

Access to Document

10.1007/s40261-016-0414-y

http://dx.doi.org/10.1007/s40261-016-0414-y

Cite this

@article{3e09353c30714dafb222b6074f8ba409,

title = "Early treatment in HCV: is it a cost-utility option from the Italian perspective?",

abstract = "Our model represents a tool for policy makers and health-care professionals, and provided information on the cost-utility of the early-treatment approach in HCV-infected patients in Italy. Starting innovative treatment regimens earlier keeps HCV-infected patients in better health and reduces the incidence of HCV-related events; generating a gain both in terms of health of the patients and correct resource allocation.",

keywords = "Business and management studies",

author = "Andrea Marcellusi and Raffaella Viti and Francesco Damele and Calogero Camma and Gloria Taliani and Mennini, \{Francesco Saverio\}",

year = "2016",

month = aug,

doi = "10.1007/s40261-016-0414-y",

language = "English",

volume = "36",

pages = "661--672",

journal = "Clinical Drug Investigation",

issn = "1173-2563",

publisher = "Adis International Ltd",

number = "8",

}

TY - JOUR

T1 - Early treatment in HCV

T2 - is it a cost-utility option from the Italian perspective?

AU - Marcellusi, Andrea

AU - Viti, Raffaella

AU - Damele, Francesco

AU - Camma, Calogero

AU - Taliani, Gloria

AU - Mennini, Francesco Saverio

PY - 2016/8

Y1 - 2016/8

N2 - Our model represents a tool for policy makers and health-care professionals, and provided information on the cost-utility of the early-treatment approach in HCV-infected patients in Italy. Starting innovative treatment regimens earlier keeps HCV-infected patients in better health and reduces the incidence of HCV-related events; generating a gain both in terms of health of the patients and correct resource allocation.

AB - Our model represents a tool for policy makers and health-care professionals, and provided information on the cost-utility of the early-treatment approach in HCV-infected patients in Italy. Starting innovative treatment regimens earlier keeps HCV-infected patients in better health and reduces the incidence of HCV-related events; generating a gain both in terms of health of the patients and correct resource allocation.

KW - Business and management studies

UR - http://www.ncbi.nlm.nih.gov/pubmed/27234943

U2 - 10.1007/s40261-016-0414-y

DO - 10.1007/s40261-016-0414-y

M3 - Article

C2 - 27234943

SN - 1173-2563

VL - 36

SP - 661

EP - 672

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

IS - 8

ER -

Early treatment in HCV: is it a cost-utility option from the Italian perspective?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this